 |
|
Discovery of natural compounds that could slow blood vessel growth
October 06, 2008Johns Hopkins researchers discover candidates for fighting disease
Using computer models and live cell experiments, biomedical engineers at the Johns Hopkins University School of Medicine have discovered more than 100 human protein fragments that can slow or stop the growth of cells that make up new blood vessels.
Reporting online last week in the Proceedings of the National Academy of Sciences, the researchers say the findings could lead to developing treatments to fight diseases that depend on the growth of new blood vessels, including cancer, macular degeneration and rheumatoid arthritis.
"Before, there were only 40 known antiangiogenesis peptides," says Aleksander Popel, Ph.D., a professor of biomedical engineering at Hopkins. "Now, using a whole-genome, computer-based approach, we have identified more than 100 new ones, all of which can be further researched for their ability to fight the more than 30 known diseases affected by excessive blood vessel growth."
To identify short protein fragments - peptides - that can block blood vessel growth, the team started by looking at 40 known peptides that have been studied and characterized by other experts in the field to stop blood vessel growth in animal models of disease. Working under the assumption that the antivessel activity of these peptides can be attributed to similar features that are shared by a number of proteins, like the sequence of the peptide building blocks, the team first categorized the 40 known peptides by where they are located and what they look like.
Having defined nine families, the researchers then used computer programs and compared the peptide families to all of the proteins encoded by the genome. They found more than 120 peptides contained in 82 different proteins, many of which were not previously known to have any activity on blood vessel development.
"Computational methods only identify potential candidates," says Popel. "We next had to do the experiments on live cells to see if they had any real activity. Of the 82 proteins we identified, most were not previously known to have any antiangiogenic activity."
To test the activity of these candidate peptides, the researchers applied them to blood vessel cells growing in the lab and examined whether they had any effect on the growth, survival and movement of these cells. To test growth and survival, they added different amounts of peptide to dishes containing roughly 2,000 cells and after three days, counted how many cells were still alive.
To test cell movement, they placed cells in double-chambered dishes and treated the cells with a growth factor known to encourage cells to move. To some of the dishes they added the test peptides. After 20 hours, they measured the number of cells that had crawled from one chamber to the other. They then identified the protein receptors that the peptides bind to and were able to show in some cases that combinations of more than one peptide were better able to stop the cells than using single peptides.
"Basic, computational studies like this are critical to understanding normal blood vessel growth," says Popel. "A better understanding of normal growth gives us a better idea of what happens in disease."
The next step, Popel says, is to test these peptides in animal models of human disease and to identify the diseases most appropriately treated by these newly identified peptide inhibitors.
Johns Hopkins Medical Institutions
"Before, there were only 40 known antiangiogenesis peptides," says Aleksander Popel, Ph.D., a professor of biomedical engineering at Hopkins. "Now, using a whole-genome, computer-based approach, we have identified more than 100 new ones, all of which can be further researched for their ability to fight the more than 30 known diseases affected by excessive blood vessel growth."
To identify short protein fragments - peptides - that can block blood vessel growth, the team started by looking at 40 known peptides that have been studied and characterized by other experts in the field to stop blood vessel growth in animal models of disease. Working under the assumption that the antivessel activity of these peptides can be attributed to similar features that are shared by a number of proteins, like the sequence of the peptide building blocks, the team first categorized the 40 known peptides by where they are located and what they look like.
Having defined nine families, the researchers then used computer programs and compared the peptide families to all of the proteins encoded by the genome. They found more than 120 peptides contained in 82 different proteins, many of which were not previously known to have any activity on blood vessel development.
"Computational methods only identify potential candidates," says Popel. "We next had to do the experiments on live cells to see if they had any real activity. Of the 82 proteins we identified, most were not previously known to have any antiangiogenic activity."
To test the activity of these candidate peptides, the researchers applied them to blood vessel cells growing in the lab and examined whether they had any effect on the growth, survival and movement of these cells. To test growth and survival, they added different amounts of peptide to dishes containing roughly 2,000 cells and after three days, counted how many cells were still alive.
To test cell movement, they placed cells in double-chambered dishes and treated the cells with a growth factor known to encourage cells to move. To some of the dishes they added the test peptides. After 20 hours, they measured the number of cells that had crawled from one chamber to the other. They then identified the protein receptors that the peptides bind to and were able to show in some cases that combinations of more than one peptide were better able to stop the cells than using single peptides.
"Basic, computational studies like this are critical to understanding normal blood vessel growth," says Popel. "A better understanding of normal growth gives us a better idea of what happens in disease."
The next step, Popel says, is to test these peptides in animal models of human disease and to identify the diseases most appropriately treated by these newly identified peptide inhibitors.
Johns Hopkins Medical Institutions
Blood Vessel Current Events and Blood Vessel News RSSResearchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Effect of real-time CPR feedback reported at resuscitation science symposium
Emergency medical service (EMS) providers in the United States assess an estimated 350,000 cardiac arrests each year. Only 5 to 10 percent of people who have sudden cardiac arrest survive. Better quality cardiopulmonary resuscitation (CPR) provided by prehospital EMS providers may be associated with better patient outcome.
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests.
Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
Key player identified in cascade that leads to hypertension-related kidney damage
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both.
Blood vessels might predict prostate cancer behavior
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
Sight gone, but not necessarily lost?
Like all tissues in the body, the eye needs a healthy blood supply to function properly. Poorly developed blood vessels can lead to visual impairment or even blindness.
Stanford study recommends change in treating pulmonary embolisms
William Kuo, MD, was the on-call interventional radiologist one Friday night three years ago when he received a call from the intensive care unit at Stanford Hospital & Clinics.
Clots traveling from lower veins may not be the cause of pulmonary embolism in trauma patients
A report from a team of Massachusetts General Hospital (MGH) physicians calls into question the longstanding belief that pulmonary embolism (PE) - the life-threatening blockage of a major blood vessel in the lungs - is caused in trauma patients by a blood clot traveling from vessels deep within the legs or lower torso.
More Blood Vessel Current Events and Blood Vessel News Articles
 |
The Fluid Mechanics of Large Blood Vessels (Cambridge Monographs on Mechanics) by T. J. Pedley (Author) The analysis of the circulation of the blood is one of the most important areas of fluid mechanics research, with far-reaching medical and physiological implications. |
 |
EcoNugenics PectaSol-C¿ Modified Citrus Pectin (270 V-caps/800mg), 0.68 lb Plastic Bottle by EcoNugenics PectaSol-C® modified citrus pectin is a highly absorbable soluble dietary fiber. This natural product is derived from the pith of citrus fruits, and is modified utilizing an enhanced process resulting in improved molecular weight and chain characteristics. PectaSol-C® product is recognized primarily for its ability to promote healthy cell growth and proliferation. |
|
Muscles and Blood Vessels Starring: Medical Student Directed By: Bill Barnett Medicines that aid the treatment of muscles and blood vessels is one of the research interests of an Asian medical student at the Morehouse School of Medicine. He discusses his research and how he manages the challenges of working toward a medical degree | |
 |
Blood Vessels - Blood Vessels - Cd, 2006 THIS IS BLOOD VESSELS - "BLOOD VESSELS" CD - 2006. SONGS: 1 Catholic Zombies 2 Escape from My Brain 3 Not Funny 4 So Long 5 When You're Young 6 Primal Urge 7 Don't Care 8 Hell Rocket 9 White Knuckle Grip 10 Complacency |
|
Blood Vessel by Blood Vessel | |
|
Mosby's Physical Examination Video Series: Video 8: Blood Vessels, Version 2 [VHS] Starring: Henry M. Seidel MD, Jane W. Ball RN DrPH CPNP NAP, Joyce E. Dains DrPH JD RN FNP BC NAP, G. William Benedict MD PhD | |
 |
Blood Vessels 101 Canvas Print - Canvas Art by FineArtAmerica.com This is a beautiful stretched-canvas art print wrapped on 2.5" thick stretcher bars. The print is professionally printed, assembled, and shipped within 2 - 3 business days from our production facility in North Carolina and arrives ready-to-hang on your wall. FineArtAmerica.com is home to more than 20,000 artists from all over the world who entrust us to fulfill their print orders online. We offer a 30-day money-back guarantee on every print that we sell and look forward to helping you select your next piece. |
 |
Blood Vessel The Cassandra Complex (Primary Contributor) |
 |
Heart Model; 3 Times Life-Size; Opens to Show Valves, Blood Vessels, Musculature by Neo/Sci Corporation Models, anatomical and cellular; Heart; 3x life-size; Separates into 4 parts; Sectioned; Shows ventricles, atria as open to expose valves, showing large blood vessels near heart and musculature of heart; Base-mounted; 7.5 x 9 x 12 in. |
 |
L-Arginine Sustained Release 350mg 360 Tablets by Healthy Origins Robert E. Kowalskys new book details entirely new, natural approaches to lowering blood pressure. His revolutionary program eliminates the need for prescription drugs for most people. He advocates L-Arginine-SR as an important part of that program. Healthy Origins® L-Arginine-SR is a unique formulation that utilizes a sustained release delivery system specifically manufactured to release the L-Arginine continuously over a 5-7 hour period. |
| © 2009 BrightSurf.com |